Association of Obesity and Breast Cancer Risk: The Role of Estrogen, Tumor Necrosis Factor-alpha, and Adiponectin as Risk factors (preliminary study) by Retnowarnadi, Ampi et al.
 Ͷͷ
Obesity and Breast Cancer Risk (Retnowardani A, et al.)
Indones  Biomed J. 2009; 1(1): 45-52 DOI: 10.18585/inabj.v1i1.82
Association of Obesity and Breast Cancer Risk:
The Role of Estrogen, Tumor Necrosis Factor-alpha, and Adiponectin                                                        
as Risk factors (preliminary study)
Ampi Retnowardani1,4, Siti Boedina Kresno2, and Mansyur Arif3
R E S E A R C H  A R T I C L E
B
ACKGROUND: Breast cancer is the most 
frequent cancer diagnosed among women. 
Many factors inﬂuence the carcinogenesis of 
breast cancer. The aim of this study to analyze the role 
of obesity (waist circumference and body mass index), 
serum Estradiol levels, TNF- , and Adiponectin in the 
occurrence of breast cancer. 
METHODS: This was observational study with case-
control design. Eleven breast cancer patients as cases 
and twelve FAM (Fibroadenoma Mammae) patients as 
controls were analyzed. The serum Estrogen, TNF-
and Adiponectin were examined in their association 
with breast cancer risk.
RESULTS: Women with breast tumor and waist 
circumference > 80 cm have signiﬁcantly higher breast 
cancer risk than women with breast tumor and waist 
circumference < 80 cm (OR 8,75; 95% CI : 1,24 – 61,88; p 
= 0,029). Women with breast tumor and higher serum 
TNF-  levels ( > 2,30 pg/ml) have higher breast cancer 
risk (19,25 times) than women with breast tumor and 
have lower serum TNF-  levels (95% CI : 1,77 -  209,55, 
p = 0,015). Whereas, women with breast tumor and 
lower Adiponectin/TNF-  ratio (< 2,13) have higher 
breast cancer risk (22,5 times) than women with breast 
tumor and higher Adiponectin/TNF-  (95% CI: 2,60 
– 194,51; p = 0,005).
CONCLUSION: These results suggest that high 
concentration of serum TNF- , waist circumference 
> 80 cm and low Adiponectin/TNF-  ratio in women 
with breast tumor are signiﬁcantly associated with an 
increased risk for breast cancer. 
KEYWORDS: Obesity, breast cancer, adiponectin/
TNF-  ratio.
Breast cancer is the most common cancer affecting 
women worldwide. Multiple risk factors are associated 
with increasing risk of breast cancer. This include 
genetic, familial and hormonal factors
The association of obesity with breast cancer 
risk, especially in post menopause women are well 
established. Aromatization of adrenal androgen into 
estrogen at adipose tissue is proposed to play role in 
the development of breast cancer.
Obese people have more adipose tissue. Adipose 
tissue is not merely a fat-storing tissue but also 
an endocrine organ, producing various cytokines 
including TNF-  and Adiponectin. TNF-  regulates 
immune responses, inﬂammation and programmed 
cell death (apoptosis). The ultimate fate of a cell 
exposed to TNF-  is determined by signal integration 
between its different effectors (1). Adiponectin is an 
adipocytokines discovered through systemic analysis 
of adipose-expressed genes. Funashashi has found the 
lower level of Adiponectin in plasma of individual 
with central obesity (2). Miyoshi and Montzoros 
reported the association of low serum Adiponectin 
levels with an increased risk for breast cancer (3,4). 
Moreover, Miyoshi also found that tumors arising in 
women with low Adiponectin levels are more likely to 
show a biologically aggressive phenotype (3).
Today, there are still few researches on the 
correlation of serum Adiponectin levels with the 
risk of breast cancer and the molecular mechanism 
which is able to explain the role of Adiponectin in 
carcinogenesis
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STUDY DESIGN AND STUDY PARTICIPANTS
This was observational study with case-control 
design, breast cancer patients as cases and FAM 
patients as controls. During 6 months period from 
March to August 2006, 90 women with breast tumor 
(suspected of breast cancer or FAM) in the screening 
centers of Rumah Sakit Kanker Dharmais Jakarta 
were identiﬁed as potential subjects. Thirty patients 
refused and 60 patients agreed to participate and were 
included in this study. Written informed consents 
as to the study were obtained from all participants. 
Information about demography, medical history, 
menstrual and menopause status, and parity was 
assessed by interview questionnaires. Anthropometric 
information(weight, height and waist circumference) 
was obtained according to standard anthropometric 
measuerement. Blood samples for Estrogen, TNF-  
and Adiponectin assay were obtained before surgery. 
Among the 60 participants, 35 patients were treated 
with excision, mastectomy, breast-conserving surgery 
or biopsy. Histological diagnosis of breast cancer was 
conﬁrmed in 11 patients, and histological  diagnosis 
of FAM was conﬁrmed in 12 patients. Final analytic 
sample included 23 participants. 
MESUREMENTS OF BIOCHEMICAL MARKERS
All venous blood samples drawn before surgery, and 
the serum was immediately separated by centrifugation 
and stored at -20OC until use. Serum Estradiol 
levels were measured by immunochemiluminescent 
using the kits from DPC (Coefﬁcient of Variation 
3.57%-9.7%). Serum TNF-  levels were measured 
Materials  and Methods
by Quantitative sandwich enzyme immunoassay 
using the kits from R&D System (Coefﬁcient of 
Variation 0.4%-14.5%). Serum Adiponectin levels 
were measured by ELISA using the kits from Daiichi 
Pure Chemicals (Coefﬁcient of Variation 2.5%). Serum 
Estradiol measurements was performed in Prodia 
Clinical Laboratory – Kramat Raya Jakarta Branch. 
Serum TNF-  and Adiponectin measurements was 
performed in Research & Development Laboratory of 
Prodia Clinical Laboratory.
STATISTICAL ANALYSIS 
Statistical analysis were performed with SPSS 
for windows ver. 11.5. Univariate analysis were 
performed to calculate mean, maximum and 
minimum value and SD. Comparison of the Body 
Mass Index, waist circumference , serum Estradiol, 
TNF- , and Adiponectin levels between cases and 
control group were analysed using Mann-Whitney 
non-parametric test. Spearman correlation statistics 
were used to determined the correlation among the 
various variables. The relationship between obesity, 
serum Estradiol levels, serum TNF-  levels, serum 
Adiponectin Levels, Adiponectin/TNF-  ratio and 
breast cancer risk were determined using crosstabs test 
to obtain OR and 95% CI. Obesity was deﬁned if BMI 
> 27 kg/m2 or waist circumference > 80 cm. Serum 
Estradiol levels was categorized according to reference 
value adjusted with menopausal or menstrual status. 
The category of serum TNF-  levels was deﬁned using 
cut off point that was calculated with ROC analysis. 
Serum Adiponectin levels and Adiponectin/TNF-a 
ratio were categorized using the median value.
Results
Table 1 shows mean values and SDs of BMI (Body 
Mass Index), waist circumference and the measured 
biomarkers between breast cancer (cases) and FAM 
(control). They reveal signiﬁcance differences of age 
(p < 0.001), BMI (p < 0.001), Waist Circumference (p = 
0.001), Adiponectin (p = 0.017) and Adiponectin/TNF-
 ratio (p=0.005) between women with breast cancer 
(cases) and women with FAM (control). Adiponectin 
and the ratio Adiponectin/TNF-  are inversely 
associated with breast cancer risk. However, no 
signiﬁcance differences of serum Estradiol and  TNF-  
levels are noted between women with breast cancer 
(cases) and women with FAM (control).
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Tabel. 1 : Basic Characteristics of Subjects (total 23 patients)
Variables FAM (Control) Breast Cancer (Cases) p
Total samples 12 11
Age (years) 27,67 + 5,91 42,27 + 10,57 < 0,001*
Body Mass Index (kg/m2) 20,36 + 2,62 25,97 + 3,19
< 0,001*
Waist Circumference (cm) 70,48 + 7,28 82,23 + 8,11
0,001*
Estradiol (pg/ml) 91,16 + 52,62 105,69 + 75,46 0,595
TNF-  (pg/ml) 1,84 + 0,87 2,93 + 1,65 0,057
Adiponectin (µg/ml) 6,17 + 2,79 3,85 + 1,25 0,017*
Rasio Adiponectin/TNF- 4,00 + 2,51 1,56 + 0,74 0,005*
FAM = Fibroadenoma Mammae, p = probability, * = statistically signiﬁcance (p < 0,05)
Correlation analysis using Spearman statistics reveal that there are no signiﬁcant correlation between age and BMI, 
waist circumference, serum Estradiol levels, serum Adiponectin levels, serum TNF-  levels, Adiponectin/TNF-
ratio. Inversely, we found signiﬁcant negative correlation between BMI and serum Adiponectin levels  (r = -0.520, 
p = 0.011), BMI and Adiponectin/TNF-  ratio (r = -0.508, p = 0.013), waist circumference and serum Adiponectin 
levels (r = -0.531, p = 0.009), waist circumference and Adiponectin/TNF-  ratio (r = -0.636, p = 0.001). Signiﬁcant 
positive correlation also noted between waist circumference and serum TNF-  levels (r = 0.526, p = 0.01).
 Table 2.  Correlation among variables
Variables rp
Body Mass Index – Serum Adiponectin levels - 0,520 0,011*
Body Mass Index – Adiponectin/TNF-  levels ratio - 0,508 0,013*
Waist Circumference – Serum TNF-  levels 0,526 0,010*
Waist circumference – Serum Adiponectin levels - 0,531 0,009*
Waist circumference – Adiponectin/TNF-  ratio - 0,636 0,001*
r = Coeﬁsien of correlation, p = probability, * = statistically signiﬁcance
Table 3 show t he r esults o f association analysis u sing crosstabs m ethod between B MI, Waist C ircumference, 
Estradiol, TNF-  Adiponectin, Adiponectin/TNF-  ratio with breast cancer incident as cases and FAM as control. 
There was evidence for signiﬁcant association between waist circumference and breast cancer risk (OR’ 8.75; 95% 
CI, 1.24 – 61.68; p = 0.029). We also found association between serum TNF-  levels with breast cancer risk and 
statistically signiﬁcant (OR, 19.25; 95% CI, 1.77 – 209.55; p = 0.015).  An inverse association between Adiponectin 
doesn’t achieve statistical signiﬁcance. However, there is evidence strong inverse  association between Adiponectin/
TNF-  ratio with Breast Cancer Risk  (OR, 22.5; 95% CI, 2.60 – 194.51; p = 0.005). For BMI and Estradiol, there is 
positive association with Breast Cancer risk but it did not achieve  statistical signiﬁcance. 
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Table 3. Association of BMI, Waist Circumference, Estradiol, TNF- , Adiponectin, Adiponectin/
TNF-  ratio with Breast Cancer Risk
Variables Cut Off OR CI, 95% p
BMI 27 kg/m2 9.17 0.86 – 97.69 0.860
Waist Circumference 80 cm 8.75 1.24 – 61.88 0.019*
Estradiol Ref. Value 9.17 0.86 – 97.69 0.066
TNF- 2.30 pg/ml 19.25 1.77 – 209.55 0.015*
Adiponectin 6.62 µg/ml 7.14 0.68 – 75.22 0.102
Adiponectin / TNF- 2.13 22.5 2.60 – 193.51 0.005*
Discussions
The association between BMI with breast cancer risk 
has been established. There are several mechanisms 
to explain Obesity cause the increasing production 
of growth-promoting steroid hormones including 
estrogen that can bind to its receptor in the nucleus of 
breast tumor cells and promote breast cancer growth 
and metastasis. 
In this study, we found that BMI in women 
 IMB naht rehgih erew stcejbus recnac tsaerb htiw
in women with FAM. From cross-tab test to analyze 
the correlation between BMI and breast cancer risk, 
we obtained OR 9.17; 95% CI 0.86-97.69, p=0.860. It 
means, this study result wasn’t similar to what has 
been previously reported. It was probably due to the 2 
subjects with extremely high BMI in FAM patients and 
small amount of samples.
In this study, the mean of waist circumference in 
breast cancer patients (82.23 + 8.11 cm) was higher 
than FAM patients (70.48 + 7.28 cm) and the difference 
was statistically signiﬁcance (p = 0.001) (Table 1). If the 
status of waist circumference was changed to obese 
(central obesity) and non-obese (normal), according 
to Indonesian Society for the study of Obesity (ISSO) 
criteria (waist circumference limit is 80 cm) then we 
got signiﬁcant correlation (p = 0.029) between breast 
cancer occurrence and waist circumference with OR 
8.75 (95% CI: 1.24 – 61.68) (Table 3).
Central obesity is often associated with the 
occurrence of insulin resistance and hyperinsulinemia. 
Increased insulin level, lead to decreasing Steroid 
Hormone Binding Globulin (SHBG) synthesis by 
the liver, and also capable to reduce the synthesis of 
Insulin-like growth factor binding protein1 (IGFBP1), 
either by the liver or by other local tissues, and in 
result, the IGFBP1 level in blood decreases as well. 
Besides, insulin stimulates insulin-like growth factor 1 
(IGF-1) synthesis. Combination of both situations can 
increase the IGF-1 bioavailability. While, recently more 
evidence show correlation between IGF-1 and the 
development of breast cancer. In MCF-7 cell culture, 
IGF-1 directly increased the ER transcriptional activity 
in the absence of Estradiol.  The presence of Estradiol 
would increase the ER transcriptional activity even 
more (5.6). The laboratory experiment showed that 
IGF family was not merely having mitogenic effect in 
breast cancer cells, but the anti-apoptotic effect as well. 
Besides, in central obesity, hiperinsulinemia takes place 
and the expression of abnormal insulin receptor can 
result in signalling deviation through Insulin Receptor 
Substrate 1 Pathway (4,6). Synergy interaction between 
the elevated Estrogen level and insulin signaling 
deviation proved to be able to increase proliferation 
activity either in normal or cancer breast cells.
In this study, the mean of Estradiol level in 
breast cancer patients (105.69 + 75.46 pg/ml) was 
not signiﬁcantly different (p = 0.595) from the mean 
of Estradiol level in FAM patients (91.16 + 52.62 pg/
ml). Standard deviation of the mean of Estradiol 
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level was too large as the tests were done in different 
menstruation periods, whereas Estradiol level shows 
variation in different periods. Related to that, normal 
or high Estradiol level was categorized based on 
the reference values according to the menstruation 
period on the sampling day. Mann-Whitney test was 
performed and we found that Estradiol value was 
signiﬁcantly different (p = 0.048) between breast cancer 
patients and FAM patients, and this result was similar 
with the references. However, categorizing Estradiol 
value like this has some disadvantages particularly 
towards the data accuracy because the data was 
obtained from interview. Difﬁculty was found during 
the interview because most of the patients were 
uncertain about the ﬁrst day of their last menstruation 
and how many days their menstruation periods were. 
Therefore, categorizing based on the assumption that 
menstruation cycle (for patients who could not answer 
the question for sure) was 28 days. Then, cross-tab test 
was performed (Table 3) and from the analysis we 
found no association between Estradiol and breast 
cancer occurrence with the odds ratio of 9.17 (95% 
CI: 0.86 – 97.69), and it wasn’t statistically signiﬁcant 
(p = 0.066). The high odds ratio but not statistically 
signiﬁcant, was probably due to the limitation in 
colleting data as previously explained.
In this study, we obtained that the mean of TNF-
 level in breast cancer patients (2.93 + 1.65 pg/ml) 
was higher compared to the mean of TNF-  level in 
FAM patients (1.84 + 0.87 pg/ml) but not statistically 
signiﬁcant with p = 0.057. When we further observed, 
we found data with extremely high TNF-  level in 
both FAM and breast cancer patients. Extremely high 
TNF-  level (6.75 pg/ml) was found in the patient 
with breast cancer along with paget’s disease of the 
nipple and clinical inﬂammation was found around the 
nipple. Besides, the interview revealed that the patient 
had analgesic/anti-inﬂammatory drug. (Patients 
having anti-inﬂammatory or infection should have 
been excluded, but because most of patients used anti-
inﬂammatory, the exclusion was not carried out). So in 
this matter, extremely high TNF-  level was inﬂuenced 
by another clinical condition (acute inﬂammation). The 
patient with extremely high TNF-  level (4.32 pg/ml) 
in FAM group appeared to be clinically healthy (there 
was no acute inﬂammation/infection), but the patient 
was one of the 2 patients in FAM group that had waist 
circumference > 80 cm, although their BMI was normal. 
Besides, the histological examination result of the 
patient showed epitheliosis (another patient with mild 
epitheliosis had rather high TNF-  level, > 2.1 pg/ml, 
while most of patients in FAM group had  TNF-  < 2 
pg/ml). From analysis of cross-tab test (Table 3) we 
found that TNF-  level correlated with breast cancer 
occurrence with odds ratio 19.25 (95% CI: 0.86 – 26,78), 
and it was statistically signiﬁcant (p = 0.015).
In individual with obesity, especially central 
obesity, TNF-  level increased. In this study, we found 
positive correlation between central obesity and TNF-
 level with r = 0.519 which was statistically signiﬁcant 
(p = 0.008)
TNF-  is pro-inﬂammatory cytokine that plays role 
in the regulation of immune response, inﬂammation 
and apoptosis. TNF-  have pleiotropic effect and cells 
that exposed to TNF-  will affected by the signal and 
activated effectors, I B kinase (IKK), c-jun-N-terminal 
protein kinase (JNK) or caspase. Activation of caspase 
trigger apoptosis, on the contrary activation of IKK 
inhibits apoptosis through the NFkB transcription 
factor.   
TNF-  acts through its receptor (TNFR1) to 
activate the NFkB transcription factor gene. In acute 
inﬂammation condition (in normal epithelial cells), 
NFkB gene activation results in increased expression 
of genes encoding pro-inﬂammatory mediators 
(cytokines), and genes that regulate the balance between 
cell proliferation and apoptosis. In inﬂammatory 
immune cells (myeloid), NFkB activation can cause 
cell death (apoptosis), but what is more important is 
to regulate the short expression of pro-inﬂammatory 
mediators to repair tissue damage. In pre-cancer 
epithelial cells, NFkB activation can increase the cell-
survival, and also the tendency to become malignant. 
It occurs because of the increase in inﬂammation & 
cell-survival gene expression and the inhibition in the 
“machine” that activates cell death (7). Apoptosis is 
a mechanism to eliminate damage or abnormal cells 
including cancer and pre-cancer cells. Related to the 
explanation and the signiﬁcant positive correlation 
between TNF-  and occurrence in breast cancer, then 
women with breast tumor (FAM) having high TNF-  
level may have higher risk to become malignant, and 
in breast cancer patients it may cause the cancer cells 
to survive more.                                    
Besides through the inﬂammatory and apoptosis 
mechanisms, TNF-  is also able to increase the 
formation of Reactive Oxygen Species (ROS) that is 
mediated by neutrophil and other cells. This process 
can cause DNA damage and inhibit DNA-repair in 
tumor cells (8).
In this study, we found that the mean of Adiponectin 
level in breast cancer patients (3.85 + 1.25 µg/ml) was 
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lower compared to the mean of Adiponectin level in 
FAM patients (6.17 + 2.79 µg/ml) and was statistically 
signiﬁcant with p = 0.017. This study result was similar 
to the result by Miyoshi (2003), Mantzoros (2004), and 
Chen (2005) who have found signiﬁcant correlation 
between Adiponectin level and breast cancer (3, 9, 
10). The former researchers used patients that had 
negative mammography results as control, while in 
this study, the control group was patients with benign 
breast tumor which was conﬁrmed to be FAM by 
histopathology.
Adiponectin is a protein exclusively secreted by 
adipocytes and acts as insulin-sensitizer (3).  Regarding 
to this, adiponectin secretion in obese subjects and 
other insulin resistance circumstances will decrease. 
In this study, we proved these phenomena and 
found a negative correlation between BMI and waist 
circumference with adiponectin level (r = -0.520 for 
BMI dan r = -0.531 for waist circumference), which 
was statistically signiﬁcant (p = 0.011 for BMI and p = 
0.009 for waist circumference).
Then we categorized the subjects based on cut off 
value of adiponectin and the median of adiponectin 
level between subjects, and analyzed them using the 
cross-tab, and we observed that adiponectin level 
didn’t correlate with the risk of breast cancer with odd 
ratio 2.40 (95% CI : 0.44 – 12.98; p = 0.309). Actually, 
categorizing the samples using median value didn’t 
have much clinical value, so we categorized the 
samples again using the mean value of healthy women 
subjects, 6.62 µg/ml (11). Based on this categorization, 
we got a higher odds ratio, i.e. 7.14 (95% CI : 0.68 – 
75.22), but this value was not statistically signiﬁcant (p 
= 0.102). Ideally, we should have used a cut off value 
obtained from analysis of ROC curve, i.e. 6.88 µg/ml, 
but when we used this value as cut off, we couldn’t 
analyze the odds ratio due to no sample in one of 
the groups. We needed a larger number of samples 
to be able to analyze this. By further observation, in 
this study, we found a subject in the breast cancer 
group having an extremely high level of adiponectin. 
This subject also had an extremely high TNF-  level. 
Besides, BMI of this subject was normal (24.94 kg/
m2) but her waist circumference was 83.3 cm (central 
obesity). In obese subjects, we usually ﬁnd high level 
of TNF-  but low level of adiponectin. Thus, this 
subject possibly had acute inﬂammation that cause 
increased level of TNF-  as well as adiponectin. This 
ﬁnding raised a question whether acute inﬂammation 
could induce an increase in adiponectin level as a 
response to that inﬂammation. This could be answered 
by an experimental study. Besides, subjects with the 
second highest adiponectin level (4.86 µg/ml) had a 
histological examination ﬁnding that differed from 
other patients, intracystic papillary carcinoma (other 
patient’s pathology anatomy ﬁndings were ductal 
carcinoma). This aroused a suspect that this high 
concentration had correlation with histopathology.
Until now, the mechanism that explains the 
relationship of adiponectin and the risk of breast 
cancer hasn’t been much known. Presently, there is no 
study towards the effect of adiponectin to breast tissues 
and breast cancer, but it is presumed that adiponectin 
can inﬂuence their growth and differentiation. In 
this study, we didn’t ﬁnd a correlation between 
adiponectin level and the estradiol level, but there 
were a correlation between adiponectin level and 
BMI and also between adiponectin level and waist 
circumference. These ﬁndings conﬁrmed the study 
done before by Miyoshi, and meant that adiponectin 
inﬂuence the risk of breast cancer, but not through 
the mechanism of estrogen. A mechanism that might 
be able to explain the relationship of adiponectin and 
breast cancer is through the insulin resistance. Insulin 
is suggested to stimulate the proliferation of breast 
cancer cells by forming a binding and stimulates the 
signaling of insulin and IGF-1 (3).
Ouchi (2000) found that Adiponectin could 
attenuate the TNF-  induced phosphorilation of I B-B 
and then activated NF B without through other signal 
transduction pathways (JNK, P38 kinase, Akt kinase) 
mediated by TNF- . NF B is an important protein in 
inﬂammation and can activate the signal transduction 
pathway in cancer cells and pre-cancer inﬂammation 
cells and can stimulate the malignancy process (12). 
In a study using rats as a model for inﬂammation 
related cancer, it was showed that NF B and TNF-  
played roles in cancer development (13). There might 
be an association between TNF-  and Adiponectin in 
carcinogenesis.
Other research supporting the role of Adiponectin 
in apoptosis process was done by Yokota, et al (2000). In 
that research, Yokota et al evaluated the expression of 
apoptosis related genes in the presence of Adiponectin 
in M1 cells. After treated with Adiponectin for 48 hours, 
there was a down-regulation of Bcl-2 (anti-apoptotic 
gene) expression, and also of Bcl-xL gene expression. 
On the contrary, adiponectin treatment didn’t have 
effect towards the regulation of pro-apoptotic gene 
expression (Bax, Bak, and p53). Thus, in obesity 
where the concentration of adiponectin is low, there 
is no down-regulation of anti-apoptotic gene, and the 
apoptosis process is blocked (14).
 ͷͳ
Obesity and Breast Cancer Risk (Retnowardani A, et al.)
Indones  Biomed J. 2009; 1(1): 45-52 DOI: 10.18585/inabj.v1i1.82
In this study, there was no direct correlation 
between TNF-  and adiponectin (r = -0.228, p = 0.272). 
Based on the theory explained above, there is an 
association between TNF-  and Adiponectin towards 
the process of apoptosis and impact in apoptosis 
process plays a role in carcinogenesis. Therefore, in 
this study, we tried to analyze the correlation between 
the ratio of Adiponectin/TNF-  and breast cancer. 
We performed a cross-tab test, but before that we 
categorized the value of Adiponectin/TNF-  ratio 
based on the median in subject population, i.e 2.13. We 
didn’t use the cut off from ROC curve analysis due to 
the small number of samples and there was no sample 
in one of the category, and in result the cross-tab test 
 .demrofrep eb t’ndluoc oitar-sddo eht etaluclac ot
According with the above theory, cross-tab analysis 
showed a correlation between Adiponectin/TNF-
ratio with the occurrence of breast cancer with odds-
ratio 22.5 (95 CI:2.60 – 194.51) which was statistically 
signiﬁcant (p = 0.005). This correlation was stronger 
and more signiﬁcant than the correlation of TNF-
 itself with the occurrence of breast cancer, and 
much stronger and signiﬁcant than the correlation of 
adiponectin itself which was weak and insigniﬁcant. 
This could be understood because Adiponectin was a 
protection while TNF-  was a risk factor and the ratio 
between both variables gave a corroborating effect. 
Adiponectin and TNF-  have been known to 
play role in carcinogenesis through the mechanism 
of inﬂammation that eventually affects the apoptosis 
process. Besides that mechanism, recent studies 
showed the possibility of other mechanism, through 
the angiogenesis process.
It is known that angiogenesis plays role in 
cancer development and from recent observations, 
it was shown that angiogenesis was also important 
in obesity. Treatment with anti-angiogenic agent 
will reduce the adipose tissue, and this shows that 
angiogenesis process is an important component in 
obesity development. Besides, it is also known that 
obese cancer patients have worse prognosis, decrease 
in disease-free interval and increase in metastasis risk. 
This also strengthen the suggestion that angiogenesis is 
increased in obesity. A study by Silha, et al (15) proved 
the increase of vascular growth factors (angiogenic 
and anti-angiogenic factors).
Angiogenesis is stimulated by hypoxia and 
erythropoiesis (EPO). Vascular Endothelial Growth 
Factor (VEGF) is the most speciﬁc angiogenesis 
inducer, produced by both normal and cancer cells 
that experience hypoxia. TNF-  blocks the synthesis of 
EPO but not the production of VEGF (16).  Burgel,  and 
Ouchi performed an experimental study using human 
umbilical vein endothelium cells (HUVECs) and 
found that Adiponectin could stimulate the growth 
of new blood vessels (angiogenesis) by stimulating 
the crosstalk between Adenosine Monophosphate-
activated protein kinase signal and Akt in endothelial 
cells (17).
Different from study by Ouchi (2004), the study 
by Brankenhielm et al showed that Adiponectin was 
a negative regulator for angiogenesis process. In 
vitro, Adiponectin attenuated the proliferation and 
migration of endothelial cells. Furthermore, the study 
by Brakenhielm et al showed that in vivo, Adiponectin 
stimulated the apoptosis of endothelial cells by 
activating the cascade pathway of caspase-8, caspase-
9, and caspase-3. These co-supporting in vitro and in 
vivo results showed that Adiponectin was a potential 
angiogenesis inhibitor. The difference between 
the study result by Brankenhielm and Ouchi was 
understood as Ouchi used endothelial cells derived 
from large blood vessel, while Brakenhielm used 
endothelial cells derived from capillary. Brakenhielm 
claimed that their choice of endothelial cells was more 
relevant to the in vivo condition, as angiogenesis 
process commonly developed from small blood vessel 
(capillary), and not the large blood vessel (17,18).
Thus, it could be concluded that Adiponectin 
played a role in carcinogenesis through inﬂammation 
process which eventually associated with apoptosis, 
and through angiogenesis.
In conclusion, we have shown a signiﬁcant 
association between high serum TNF-  levels, waist 
circumference  80 cm, low Adiponectin/TNF- ratio 
and increasing risk for breast cancer. However, we 
have not found a signiﬁcant association between 
high serum Estradiol levels and/or low Adiponectin 
levels with breast cancer risk. The results suggest 
that waist circumference, serum TNF-  levels and 
Adiponectin/TNF-  ratio might be used as a breast 
cancer risk predictor in women with breast tumor. In 
addition, Adiponectin/TNF-a ratio was the strongest 
predictor for breast cancer risk (OR 22.5). The 
limitation of this study because of the disign of this 
study is observational case-control study that cannot 
indicate causal relationship, selection bias and samples 
heterogenity. A large number of subjects is needed to 
conﬁrmed  our preliminary results.
ͷʹ
The Indonesian Biomedical Journal, Vol.1, No.1, April 2009, p.45-52 Print ISSN: 2085-3297, Online ISSN: 2355-9179
Acknowledgement:
The Authors thank the Prodia Foundation for Research and 
Training for the invaluable support in this research. And thank to 
Dharmais Cancer Hospital for technical assistance in collecting 
samples in this research, especialy to Samuel Haryono, MD., 
Sutjipto, MD., and Ramadhan, MD.
References:
1. Tang, G. et al.  Inhibition of JNK Activation Through NF-kB Target 
Genes. Nature 2001; 414 : 313-317 
2. Funahashi, T., Matsuzawa, Y., Kihara, S.  Adiponectin as Potensial 
Key Player in Metabolic Insights into Atherosclerosis, 
Diabetes and cancer. International Congress Series 2004; 
1262: 368-371. (online). (http://www.ics-elsevier.com, 
download September 2005)
3. Mantzoros, C. et al. Adiponectin and Breast Cancer Risk.  J  Clin 
Endocrinol  Metab 2004; 89 : 1102-1107. (online). (http://
www.jcem. endojournals.org, download Januari 1st 2006)
4. Stoll, B.A. Upper Abdominal Obesity, Insulin Resistance and 
Breast Cancer Risk. Int. J. of Obesity 2002; 26 : 747-753
5. Cance, M. and Kathryn L. Estrogen and Insulin Crosstalk: Breast 
Cancer Risk Implication, (online), (http://www.nursingcenter.
com, 2003, download June 12th2006)
6. Calle, E.E. and Kaaks, R. Overweight, Obesity and Cancer: 
Epidemiological Evidence and Proposed Mechanisms. 
Nature 2004, 4: 579-591 (http://www.nature.com/reviews/
cancer, download June 12th 2006)
7. Balkwill, F. and Coussens, LM. An Inﬂammatory Link. Nature; 
2004 431:405-406
8. Shacter, E.PhD. and Weitzman, S.A. MD. Chronic Inﬂamation 
and Cancer. Oncology 2002; 16 : 217-232. (online). (http://
www.cancernetwork.com/journals/oncology, download 
December 24th 2004)
9. Miyoshi, Y., Funahashi, T., Kihara, S., Taguchi, T., Tamaki, Y., 
Matsuzawa, Y., and Noguchi, . Association of Serum 
Adiponectin Levels with Breast Cancer Risk.  Clin  Cancer 
Res 2003; 9 : 5699-5704
10. Chen, DC. et.al. Serum Adiponectin and Leptin Levels in 
Taiwanese Breast Cancer Patients. Cancer Lett. (online). 
(http://www. pubmed.gov, diakses November 15th2005)
11. Ebinuma, H., Miyazaki, O., Yago, H., Hara, K., Yamauchi, 
T. Kadowaki, T. A Novel ELISA System for Selective 
Measurement of Human Adiponectin Multimers by Using 
Proteases. Clin. Chim. Acta, 2006 (online), (http://www.
sciencedirect.com), download July 2006
12. Ouchi, N. et al.  Adiponectin an Adipocyte-Derived Plasma 
Protein, Inhibits Endothelial NF- B Signalling Through a 
cAMP-Dependent Pathway. Circulation 2000; 102: 1296-
1301
13. Pikarsky, E. et al. NF- B Function as Tumour Promoter in 
Inﬂammation-Associated Cancer. Nature 2003; 431 : 461-
466
14. Yokota, T. et al. Adiponectin, a New Member of the Family of 
Soluble Defense Collagens, Negatively Regulates the 
Growth of Myelomonocytic Progenitors and the Functions 
of Macrophages. Blood 2000; 96 (5) : 1723-1732
15. Silha, J.V., Krsek, M., Sucharda, P. and Murphy, L.J. Angiogenic 
Factors are Elevated in Overweight and Obese Individuals. 
Int. J. of Obesity 2005; 29 : 1308-1314.
16. Burgel, T.H., Rutkowski, K., Metzen, E., Fandrey, J., and 
Jelkmann, W. Blood 1999; 94 : 1561-1567
17. Ouchi, N. et al. Adiponectin Stimulates Angiogenesis by 
Promoting Cross-talk Between AMP-activated Protein 
Kinase and Akt Signalling in Endothelial Cells. J. Biol. 
Chem. 2004; 279 : 1304-1309
18. Brakenhielm, E. et al. Adiponectin-induced Antiangiogenesis and 
Antitumor Activity Involve Caspase-mediated Endothelial 
Cell Apoptosis, 2004 (online), (http://www.pnas.org/cgi/
doi/10.1073, download June12th 2006).
